Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Trials

Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience

Bone Marrow Transplantation volume 37, pages 219–221 (2006)Cite this article

Abstract

We evaluated the number and characteristics of randomized controlled trials (RCTs) addressing hematopoietic stem cell transplantation (HSCT) for patients with hematological malignancies, comparing the productivity of US and Europe. A MEDLINE search was conducted to identify all published RCTs for the management of adult patients with hematological malignancies from January 1992 to December 2003. Eighty-three of the 306 trials identified included HSCT as one of the treatment arms. The US produced 25, Europe 54, and all other countries four. Four European countries, France, Italy, Germany, and UK (FIGU), produced 32 out of the 54 European studies. Significant differences emerged when focus of the study and accrual numbers were analyzed. Trials comparing HSCT to standard dose therapy represented 34.9% of the 83 trials and 59.4% of FIGU trials, but only 4% of US studies (P=0.001). US trials accrued a mean of 110.2 patients per study, as compared to 222.6 in FIGU studies (P=0.006) and 205.3 when all non-US countries are considered (P=0.01). Our conclusions are that US transplant RCT have focused on issues other than the comparison of HSCT to standard therapies. There is serious paucity of US trials defining the role of HSCT in the management of hematological malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Simon R . Design and Analysis of Clinical Trials. In: De Vita V, Hellman S, Rosemberg SA (eds). Cancer: Principles & Practice, 6th edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 521–538.

    Google Scholar 

  2. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Task Force, 2nd edn. Williams & Wilkins: Baltimore, MD, 1996.

  3. Stossel TP, Stossel SG . Declining American representation in leading Clinical-Research Journals. N Engl J Med 1990; 322: 739–742.

    Article  CAS  Google Scholar 

  4. Friedman MA, Cain DF, Bronzert D, Wu RS . Poor funding rates of cancer clinical research: intractable problem or solvable challenge? J Nat Cancer Inst 1991; 83: 838–841.

    Article  CAS  Google Scholar 

  5. Freireich EJ . A study of the status of clinical cancer research in the United States. J Natl Cancer Inst 1991; 83: 829–837.

    Article  CAS  Google Scholar 

  6. Cassileth BR . Clinical trials: time for action. J Clin Oncol 2003; 21: 765–766.

    Article  Google Scholar 

  7. O'Reilly RJ . Clinical trials of hematopoietic cell transplantation: current needs and future strategies. Biol Blood Marrow Transplant 2000; 6: 79–89.

    Article  CAS  Google Scholar 

  8. Hillner BE . Trends in clinical trials reports in common cancers between 1989 and 2000. J Clin Oncol 2003; 21: 1850–1858.

    Article  Google Scholar 

  9. Dickersin K, Scherer R, Lefebvre C . Systematic reviews: identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286–1291.

    Article  CAS  Google Scholar 

  10. International Bone Marrow Transplant Registry/American Bone Marrow Transplant Registry, Annual Publication, 2003.

  11. Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A . Haematopoietic Stem Cell Transplantation (HSCT) in Europe 2002. Changes in indications and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 2004; 34: 855–875.

    Article  CAS  Google Scholar 

  12. Wright JR, Whelan TJ, Schiff S, Dubois S, Crooks D, Haines PT et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol 2004; 22: 4312–4318.

    Article  Google Scholar 

  13. Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E . Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003; 21: 830–835.

    Article  Google Scholar 

  14. Scherer FM . The pharmaceutical industry-prices and progress. N Engl J Med 2004; 351: 927–932.

    Article  CAS  Google Scholar 

  15. Bodenheimer T . Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539–1544.

    Article  CAS  Google Scholar 

  16. Gross CP, Murthy V, Li Y, Kaluzny AD, Krumholz HM . Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 2004; 96: 1063–1069.

    Article  CAS  Google Scholar 

  17. Corrie P, Shaw J, Harris R . Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study. BMJ 2003; 327: 320–321.

    Article  Google Scholar 

  18. Natham D, Varmus HE . The national institutes of health and clinical research: a progress report. Nat Med 2000; 6: 1202–1204.

    Google Scholar 

  19. Natham DG, Wilson JD . Clinical research and the NIH-A report card. N Engl J Med 2003; 349: 1860–1865.

    Article  Google Scholar 

  20. Crowley WF, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H et al. Clinical research in the United States at a crossroads: proposal for a novel public–private partnership to establish a National Clinical Research Enterprise. JAMA 2004; 291: 1120–1126.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Medical College of Georgia, Augusta, GA, USA

    S S Kuthiala & O F Ballester

  2. Section of Hematology/Oncology, University of Rochester, Rochester, NY, USA

    G H Lyman

Authors
  1. S S Kuthiala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G H Lyman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O F Ballester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S S Kuthiala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuthiala, S., Lyman, G. & Ballester, O. Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience. Bone Marrow Transplant 37, 219–221 (2006). https://doi.org/10.1038/sj.bmt.1705230

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705230

Keywords

Search

Advanced search

Quick links